Drug intelligence / Profile preview

JYS4-2

Development stage: Preclinical
Lead developer: Jiuyuan Gene Engineering
Modality: Antibody-Based Therapeutics

Overview

JYS4-2 is a Class 1 biological new drug candidate being developed by Hangzhou Jiuyuan Genetic Biopharmaceutical for the treatment of obesity and overweight. It is characterized as a polyclonal antibody biologic. The drug received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) in the second quarter of 2021. While it is part of the developer's metabolic disease pipeline, specific details regarding its molecular target and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on JYS4-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JYS4-2.

Explore the full profile